While surgery remains an important option for severe cases, it carries notable risks, including a 30–50% chance of symptom recurrence within five years. By contrast, modern pharmacological treatments ...

Around half of participants reported improvements in their pain after adopting at least one of these diets. For the most ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

In a report released yesterday, Alistair Campbell from RBC Capital maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA ...

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

The Hormone Replacement Therapy Market is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.

Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy after Gedeon Richter's Ryeqo was cleared for NHS use. This morning, NICE recommended ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales. Theramex's GnRH antagonist Yselty (linzagolix ...

DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...